leadf
logo-loader
viewOpyl Ltd

ShareRoot advancing audit of company strategy and proprietary technologies

The company operates in the social media marketing and privacy protection ecosystem

technology ecosystem
Last month, ShareRoot entered a collaboration with Cancer Trials Australia

ShareRoot Ltd (ASX:SRO) is progressing an audit of company strategy and proprietary technologies which is expected to be completed by the end of the month.

ShareRoot chairman Harvey Kaplan said: “Considering the recent change in operational and strategic leadership it is appropriate that the board undertakes a thorough review of the company’s progress to date and the current and prospective value of the assets.”

READ: ShareRoot collaborates to support cancer research with MediaConsent

Last month, the company entered a collaboration that will see its MediaConsent platform used in a cancer clinical trial setting.

The collaboration is with Cancer Trials Australia (CTA) and the medical project is being led by The Social Science (TSS).

The MediaConsent Medical project now has three health or medical research related collaborators being St Vincent’s Hospital, Melbourne, Neuroscience Trials Australia, and CTA.

The shared goal with the MediaConsent clinical collaboration is to demonstrate how ShareRoot’s technology protects patient data and privacy whilst supporting the advancement of clinical research.

Quick facts: Opyl Ltd

Price: 0.155 AUD

ASX:OPL
Market: ASX
Market Cap: $5.72 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Opyl Ltd named herein, including the promotion by the Company of Opyl Ltd in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Opyl Ltd CEO says successful COVID-19 data trial is validation of its platform

Opyl Ltd's (ASX:OPL) Michelle Gallaher updates Proactive's Andrew Scott on developments with their clinical predictor and clinical trials recruitment platforms. The company's developed software that uses artificial intelligence (AI) to make a probability of success prediction on the likelihood...

on 18/11/20

2 min read